Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.

ABSTRACT: BACKGROUND:Metastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies need new medication for further treatment. Famitinib is a small-molecule multikinase inhibitor, with promising anticancer activities. This multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial was designed to evaluate the safety and efficacy of famitinib in mCRC. METHODS:Famitinib or placebo was administered orally once daily. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), quality-of-life (QoL), and safety. RESULTS:Between July 18, 2012 and Jan 22, 2014, a total of 167 patients were screened, and 154 patients were randomi

SUBMITTER: Xu RH 

PROVIDER: S-EPMC5741870 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature